tiprankstipranks
Advertisement
Advertisement
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
PremiumRatingsAcrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
3M ago
Acrivon Biosciences: Advancing ACR‑368 and ACR‑2316 Pipeline Underpins Buy Rating and Long Cash Runway
Premium
Ratings
Acrivon Biosciences: Advancing ACR‑368 and ACR‑2316 Pipeline Underpins Buy Rating and Long Cash Runway
3M ago
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials
Premium
Ratings
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials
3M ago
Acrivon Therapeutics sees cash runway into 2Q27
PremiumThe FlyAcrivon Therapeutics sees cash runway into 2Q27
5M ago
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon
Premium
Ratings
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon
6M ago
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
Premium
Company Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
6M ago
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
PremiumRatingsFocused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
7M ago
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
7M ago
Acrivon Showcases Promising Phase 2b Oncology Data Update
Premium
Company Announcements
Acrivon Showcases Promising Phase 2b Oncology Data Update
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100